Intranasal Naloxone for Opioid Overdose

Author/s: 
Jessica L Taylor, Karen E Lasser
Date Added: 
January 3, 2024
Journal/Publication: 
JAMA
Publisher: 
American Medical Association
Publication Date: 
December 21, 2023
Type: 
Meta-analyses, Reviews, and Guidelines
Format: 
Article
DOI (1): 
10.1001/jama.2023.23248
PMID (1): 
38127361

RPR Commentary

A summary of intranasal naloxone for treatment of opioid overdose. James W. Mold, MD, MPH

Abstract

In 2021, opioid overdose deaths exceeded 80 000 in the US.1 Naloxone, a competitive opioid receptor antagonist that reverses symptoms of opioid intoxication and overdose by displacing opioids from μ-opioid receptors, is a safe and effective medication for preventing opioid overdose death. Naloxone meets US Food and Drug Administration (FDA) criteria for approval without a prescription: its benefits outweigh risks, it treats a condition that can be identified by people in the community, it has a low potential for misuse, and it can be labeled to facilitate correct administration.

Text Availability

Commercial full text (fees may apply)